Undisclosed cyclin inhibitor
/ Boehringer Ingelheim, Circle Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 23, 2025
Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(Businesswire)
- "Oral macrocyclic cyclin D1 RxL inhibition demonstrates potent and selective disruption of cyclin D1–Rb interaction with robust anti-tumor activity in multiple cancer models. Nomination of development candidate expected by year-end 2025."
Pipeline update • Preclinical • Estrogen Receptor Positive Breast Cancer • Mantle Cell Lymphoma • Oncology
1 to 1
Of
1
Go to page
1